FDA draft guidance aims to reduce animal testing in cancer drug development

The FDA has issued draft guidance to reduce unnecessary animal testing in nonclinical safety assessments for certain cancer drugs.Once finalized, this would reduce the time it takes for new cancer drugs to go from discovery to patient use.

venerdì 29 maggio 2026 New tab

413 words~2 min read

May 29, 2026

1 min read

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

FDA draft guidance aims to reduce animal testing in cancer drug development

FDA draft guidance aims to reduce animal testing in cancer drug development

Other newsrooms on this story

Related reading

FDA Sets Sights on Animal Testing; AI Privacy Threat; Chewing Gum for Cancer?

Q&A: FDA update to biosimilar approval process may reduce time, cost of…

FDA launches effort to speed up clinical trials, using AI

FDA to reconsider treatment for rare cancer after its surprise rejection

FDA floats possible approach to repurpose approved drugs under new uses

FDA revisits a rare cancer treatment it rejected a few months ago

Other newsrooms on this story

Related reading

FDA Sets Sights on Animal Testing; AI Privacy Threat; Chewing Gum for Cancer?

Q&A: FDA update to biosimilar approval process may reduce time, cost of…

FDA launches effort to speed up clinical trials, using AI

FDA to reconsider treatment for rare cancer after its surprise rejection

FDA floats possible approach to repurpose approved drugs under new uses

FDA revisits a rare cancer treatment it rejected a few months ago